Table 2 Pre-clinical inhibitors or blocking antibodies that target Notch signaling
From: The Notch signaling pathway: a potential target for cancer immunotherapy
Name | Class | Type of tumor | Function | Reference |
|---|---|---|---|---|
NVS-ZP7-4 | Inhibitor that inhibits the synthesis of pre-Notch receptors | T-ALL | Interacts with ZIP7, increases ER Zn2+ levels, and inhibits the synthesis of pre-Notch receptors | [16] |
FLI-06 | Inhibitor that inhibits the synthesis of pre-Notch receptors | ESCC | Inhibits Notch trafficking and processing,  and prevents the early secretion of Notch signaling | [23] |
CTX014 | Anti-Jagged 1/2 mAb | Solid tumor | Overcomes tumor-induced T cell tolerance, increases the infiltration of reactivated CD8+ T cells into tumors, and enhances the efficacy of T cell–based immunotherapy | [17] |
ZLDI-8 | ADAM inhibitor | HCC | Inhibits tumor growth in nude HCC-bearing mouse model | [18] |
DAPT | γ-secretase inhibitor | HNSCC | Enhances tumor immunity in HNSCC | [19] |
SAHM1 | Notch transcription complex inhibitor | T-ALL | Suppress genome-wide suppression of Notch-activated genes in leukemic cells | [20] |
IMR-1 | Notch transcription complex inhibitor | EAC | Inhibits the growth of Notch-dependent EAC patient-derived xenograft tumors | [21] |